CN117412747A - 用于治疗激越的方法和组合物 - Google Patents
用于治疗激越的方法和组合物 Download PDFInfo
- Publication number
- CN117412747A CN117412747A CN202280027623.0A CN202280027623A CN117412747A CN 117412747 A CN117412747 A CN 117412747A CN 202280027623 A CN202280027623 A CN 202280027623A CN 117412747 A CN117412747 A CN 117412747A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- dosage form
- subject
- dexmedetomidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163154281P | 2021-02-26 | 2021-02-26 | |
| US63/154,281 | 2021-02-26 | ||
| PCT/US2022/017963 WO2022183029A1 (en) | 2021-02-26 | 2022-02-25 | Methods and compositions for treating agitation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117412747A true CN117412747A (zh) | 2024-01-16 |
Family
ID=83048476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280027623.0A Pending CN117412747A (zh) | 2021-02-26 | 2022-02-25 | 用于治疗激越的方法和组合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20240139169A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4297871A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024507991A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117412747A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3208828A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202302094A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022183029A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL267689B2 (en) | 2016-12-31 | 2025-05-01 | Bioxcel Therapeutics Inc | Use of sublingual dexmedetomidine for the treatment of agitation |
| IL279713B2 (en) | 2018-06-27 | 2025-01-01 | Bioxcel Therapeutics Inc | Dexmedetomidine-containing layer compositions and methods for their production |
| EP3999058A4 (en) | 2019-07-19 | 2023-05-03 | Bioxcel Therapeutics, Inc. | TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN |
| AU2020407163A1 (en) * | 2019-12-16 | 2022-07-21 | Minute Molecular Diagnostics, Inc. | Lyophilized reagents |
| EP4580619A1 (en) * | 2022-08-31 | 2025-07-09 | BioXcel Therapeutics, Inc. | Methods and compositions for treating acute stress disorder |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| WO2024211911A1 (en) * | 2023-04-07 | 2024-10-10 | Oaktree Fund Administration, Llc | Methods for treating depressive states |
| WO2024263973A1 (en) * | 2023-06-23 | 2024-12-26 | Bioxcel Therapeutics, Inc. | Dexmedetomidine treatment regimens |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1138164A1 (ru) * | 1963-04-25 | 1985-02-07 | Shadurskij Konstantin S | Антигистаминное средство "димебон |
| US20070117835A1 (en) * | 2005-10-04 | 2007-05-24 | David Hung | Methods and compositions for treating Huntington's disease |
| US20100152108A1 (en) * | 2006-10-27 | 2010-06-17 | Medivation Neurology, Inc. | Methods and combination therapies for treating alzheimer's disease |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2243468A1 (en) * | 2009-04-17 | 2010-10-27 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally Disintegrating Dimebolin Compositions |
| WO2011039686A1 (en) * | 2009-09-30 | 2011-04-07 | Pfizer Inc. | Latrepirdine oral sustained release dosage forms |
| US20110172262A1 (en) * | 2008-09-15 | 2011-07-14 | Biovista, Inc. | Compositions and methods for treating epilepsy |
| US20110269777A1 (en) * | 2007-08-01 | 2011-11-03 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| WO2013114400A2 (en) * | 2012-01-20 | 2013-08-08 | Rubicon Research Private Limited | Compressed pharmaceutical compositions of atypical antipsychotics |
| EP2774991A1 (en) * | 2013-03-06 | 2014-09-10 | Life Science Inkubator Betriebs GmbH & Co. KG | Drug delivery system for use in the treatment or diagnosis of neurological disorders |
| CN104530413A (zh) * | 2014-10-01 | 2015-04-22 | 厦门赛诺邦格生物科技有限公司 | 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质 |
| WO2016061554A1 (en) * | 2014-10-16 | 2016-04-21 | Bioxcel Corporation | Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof |
| US20170239221A1 (en) * | 2014-10-15 | 2017-08-24 | Bioxcel Corporation | Prevention or treatment of sleep disorders using dexmedetomidine formulation |
| CN110337290A (zh) * | 2016-12-31 | 2019-10-15 | 比奥克斯塞尔医疗股份有限公司 | 舌下右旋美托咪啶用于治疗激越的用途 |
| WO2020006092A1 (en) * | 2018-06-27 | 2020-01-02 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
| WO2021016112A2 (en) * | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| CN116615243A (zh) * | 2020-10-08 | 2023-08-18 | 比奥克斯塞尔医疗股份有限公司 | 使用右美托咪啶盐酸盐治疗躁郁症和精神病 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2200610T3 (cg-RX-API-DMAC7.html) * | 2007-09-21 | 2018-06-09 | ||
| WO2009039461A2 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| JP6013364B2 (ja) * | 2010-12-23 | 2016-10-25 | アルカーメス ファーマ アイルランド リミテッド | マルチプルapiローディングプロドラッグ |
-
2022
- 2022-02-25 EP EP22760513.6A patent/EP4297871A4/en active Pending
- 2022-02-25 CN CN202280027623.0A patent/CN117412747A/zh active Pending
- 2022-02-25 US US18/278,786 patent/US20240139169A1/en not_active Abandoned
- 2022-02-25 JP JP2023552197A patent/JP2024507991A/ja active Pending
- 2022-02-25 CA CA3208828A patent/CA3208828A1/en active Pending
- 2022-02-25 WO PCT/US2022/017963 patent/WO2022183029A1/en not_active Ceased
- 2022-02-25 TW TW111107146A patent/TW202302094A/zh unknown
-
2024
- 2024-08-22 US US18/812,515 patent/US20250228833A1/en active Pending
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1138164A1 (ru) * | 1963-04-25 | 1985-02-07 | Shadurskij Konstantin S | Антигистаминное средство "димебон |
| US20070117835A1 (en) * | 2005-10-04 | 2007-05-24 | David Hung | Methods and compositions for treating Huntington's disease |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20100152108A1 (en) * | 2006-10-27 | 2010-06-17 | Medivation Neurology, Inc. | Methods and combination therapies for treating alzheimer's disease |
| US20110269777A1 (en) * | 2007-08-01 | 2011-11-03 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| US20110172262A1 (en) * | 2008-09-15 | 2011-07-14 | Biovista, Inc. | Compositions and methods for treating epilepsy |
| EP2243468A1 (en) * | 2009-04-17 | 2010-10-27 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally Disintegrating Dimebolin Compositions |
| WO2011039686A1 (en) * | 2009-09-30 | 2011-04-07 | Pfizer Inc. | Latrepirdine oral sustained release dosage forms |
| WO2013114400A2 (en) * | 2012-01-20 | 2013-08-08 | Rubicon Research Private Limited | Compressed pharmaceutical compositions of atypical antipsychotics |
| EP2774991A1 (en) * | 2013-03-06 | 2014-09-10 | Life Science Inkubator Betriebs GmbH & Co. KG | Drug delivery system for use in the treatment or diagnosis of neurological disorders |
| CN104530413A (zh) * | 2014-10-01 | 2015-04-22 | 厦门赛诺邦格生物科技有限公司 | 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质 |
| US20170239221A1 (en) * | 2014-10-15 | 2017-08-24 | Bioxcel Corporation | Prevention or treatment of sleep disorders using dexmedetomidine formulation |
| WO2016061554A1 (en) * | 2014-10-16 | 2016-04-21 | Bioxcel Corporation | Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof |
| CN110337290A (zh) * | 2016-12-31 | 2019-10-15 | 比奥克斯塞尔医疗股份有限公司 | 舌下右旋美托咪啶用于治疗激越的用途 |
| WO2020006092A1 (en) * | 2018-06-27 | 2020-01-02 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
| WO2021016112A2 (en) * | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| CN116615243A (zh) * | 2020-10-08 | 2023-08-18 | 比奥克斯塞尔医疗股份有限公司 | 使用右美托咪啶盐酸盐治疗躁郁症和精神病 |
Non-Patent Citations (1)
| Title |
|---|
| ROSSI G,等: "Management of Agitation in Huntington’s Disease: A Review of the Literature", CUREUS, vol. 12, no. 08, 14 August 2020 (2020-08-14) * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250228833A1 (en) | 2025-07-17 |
| JP2024507991A (ja) | 2024-02-21 |
| EP4297871A4 (en) | 2025-01-01 |
| WO2022183029A1 (en) | 2022-09-01 |
| EP4297871A1 (en) | 2024-01-03 |
| CA3208828A1 (en) | 2022-09-01 |
| TW202302094A (zh) | 2023-01-16 |
| US20240139169A1 (en) | 2024-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250228833A1 (en) | Methods and compositions for treating agitation | |
| JP7008153B2 (ja) | 激越の治療のための舌下デクスメデトミジンの使用 | |
| Fu et al. | Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies | |
| JP2013539790A (ja) | メマンチンを含む鎮咳組成物 | |
| MXPA06000529A (es) | Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas. | |
| JP2010248106A (ja) | フィルムコーティング錠 | |
| JP2023545372A (ja) | デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療 | |
| US20130274342A1 (en) | Compositions and methods for treating cough | |
| CN1173701C (zh) | 含有米氮平的口内崩解组合物 | |
| KR20240089377A (ko) | 자폐 스펙트럼 장애를 갖는 대상체를 치료하기 위한 방법 및 생성물 | |
| JP6061924B2 (ja) | 口腔内分散性製剤 | |
| US20090269393A1 (en) | Chewable Bilayer Tablet Formulation | |
| TW202416979A (zh) | 用於治療急性壓力症之方法及組合物 | |
| JP2019515045A (ja) | 甲状腺ホルモン又はそのアナログを提供する組成物及び方法 | |
| Nagpal et al. | Patent innovations in fast dissolving/disintegrating dosage forms | |
| WO2025128666A1 (en) | Combination of latrepirdine and a pharmacokinetic stabilizer | |
| PHARMACEUTICS | FORMULATION AND CHARACTERIZATION OF RIZATRIPTAN BENZOATE SUBLINGUAL TABLET WITH VARIOUS PERMEATION ENHANCERS | |
| HK40014031A (en) | Use of sublingual dexmedetomidine for the treatment of agitation | |
| HK1242579A1 (en) | Oral therapeutic compound delivery system | |
| JP2010100550A (ja) | 医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |